TRANSVAC

European Network of Vaccine Development and Research

 Coordinatore EUROPEAN VACCINE INITIATIVE - EEIG 

 Organization address address: IM NEUERHEIMER FELD 307
city: Heidelberg
postcode: 69120

contact info
Titolo: Dr.
Nome: Odile
Cognome: Leroy
Email: send email
Telefono: 496222000000
Fax: 496222000000

 Nazionalità Coordinatore Germany [DE]
 Totale costo 11˙871˙094 €
 EC contributo 9˙899˙999 €
 Programma FP7-INFRASTRUCTURES
Specific Programme "Capacities": Research infrastructures
 Code Call FP7-INFRASTRUCTURES-2008-1
 Funding Scheme CP-CSA-Infra
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-10-01   -   2013-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    EUROPEAN VACCINE INITIATIVE - EEIG

 Organization address address: IM NEUERHEIMER FELD 307
city: Heidelberg
postcode: 69120

contact info
Titolo: Dr.
Nome: Odile
Cognome: Leroy
Email: send email
Telefono: 496222000000
Fax: 496222000000

DE (Heidelberg) coordinator 2˙116˙215.80
2    STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER

 Organization address address: LANGE KLEIWEG 161
city: RIJSWIJK ZH
postcode: 2288 GJ

contact info
Titolo: Mr.
Nome: Willem
Cognome: Slingerland
Email: send email
Telefono: +31 015 2842500
Fax: +31 015 284 2600

NL (RIJSWIJK ZH) participant 1˙404˙380.40
3    MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.

 Organization address address: Hofgartenstrasse 8
city: MUENCHEN
postcode: 80539

contact info
Titolo: Prof.
Nome: Stefan H.E.
Cognome: Kaufmann
Email: send email
Telefono: +49 30 28460 500
Fax: +49 30 28460 501

DE (MUENCHEN) participant 979˙495.00
4    LIONEX GMBH

 Organization address address: Salzdahlumer Strasse 196
city: BRAUNSCHWEIG
postcode: 38126

contact info
Titolo: Prof.
Nome: Mahavir
Cognome: Singh
Email: send email
Telefono: +49 531 2601266
Fax: +49 531 2601159

DE (BRAUNSCHWEIG) participant 959˙975.00
5    Department of Health

 Organization address address: Quarry House, Quarry Hill
city: Leeds
postcode: LS2 7UE

contact info
Titolo: Mrs.
Nome: Cathy
Cognome: Rowe
Email: send email
Telefono: +44 1980 612812

UK (Leeds) participant 956˙354.56
6    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

 Organization address address: University Offices, Wellington Square
city: OXFORD
postcode: OX1 2JD

contact info
Titolo: Mr.
Nome: Gary
Cognome: Strickland
Email: send email
Telefono: +44 1865 857 432
Fax: +44 1865 222 901

UK (OXFORD) participant 900˙495.00
7    UNIVERSITE DE LAUSANNE

 Organization address city: LAUSANNE
postcode: 1015

contact info
Titolo: Mr.
Nome: Gerard
Cognome: Mareine
Email: send email
Telefono: +41 21 692 2329
Fax: +41 21 692 2305

CH (LAUSANNE) participant 656˙775.56
8    STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK

 Organization address address: Costerweg 50
city: WAGENINGEN
postcode: 6701BH

contact info
Titolo: Dr.
Nome: Norbert
Cognome: Stockhofe
Email: send email
Telefono: +31 320 238382
Fax: +31 320 238050

NL (WAGENINGEN) participant 586˙018.06
9    HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH

 Organization address address: Inhoffenstrasse 7
city: BRAUNSCHWEIG
postcode: 38124

contact info
Titolo: Dr.
Nome: Michael
Cognome: Straetz
Email: send email
Telefono: +49 531 6181 2020
Fax: +49 531 6181 2299

DE (BRAUNSCHWEIG) participant 577˙460.30
10    LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE

 Organization address address: KEPPEL STREET
city: LONDON
postcode: WC1E7HT

contact info
Titolo: Ms.
Nome: Penny
Cognome: Ireland
Email: send email
Telefono: +44 20 7927 2678
Fax: +44 7636 7679

UK (LONDON) participant 339˙000.00
11    UNIVERSITAET REGENSBURG

 Organization address address: UNIVERSITAETSSTRASSE 31
city: REGENSBURG
postcode: 93053

contact info
Titolo: Dr.
Nome: Christian
Cognome: Blomeyer
Email: send email
Telefono: +49 941 943 2309
Fax: +49 941 943 1545

DE (REGENSBURG) participant 229˙006.81
12    "ID-LELYSTAD, INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID B.V."

 Organization address address: Edelhertweg 15
city: LELYSTAD
postcode: 8219PH

contact info
Titolo: Dr.
Nome: Jelle
Cognome: Thole
Email: send email
Telefono: +31 320 238 508
Fax: +31 320 238 050

NL (LELYSTAD) participant 86˙615.36
13    STICHTING TUBERCULOSIS VACCINE INITIATIVE

 Organization address address: Runderweg 6
city: LELYSTAD
postcode: 8219 PH

contact info
Titolo: Dr.
Nome: Jelle
Cognome: Thole
Email: send email
Telefono: +31 320 238508
Fax: +31 320 238050

NL (LELYSTAD) participant 85˙107.28
14    Vakzine Projekt Management GmbH

 Organization address address: Mellendorfer Strasse 9
city: Hannover
postcode: 30625

contact info
Titolo: Dr.
Nome: Leander
Cognome: Grode
Email: send email
Telefono: +49 51116990814
Fax: +49 511 169908 29

DE (Hannover) participant 23˙100.00
15    HEALTH PROTECTION AGENCY HPA

 Organization address address: Central Office - 7th Floor, Holborn Gate - High Holborn 330
city: LONDON
postcode: WC1V 7PP

contact info
Titolo: Dr.
Nome: Steve
Cognome: White
Email: send email
Telefono: +44 1980 612186
Fax: +44 1980 612216

UK (LONDON) participant 0.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

tbvi    community    types    animal    stakeholders    stakeholder    accessible    protocols    harmonised    pre    models    transvac    rapid    formulations    validation    groups    responses    vaccine    antigens    candidates    developers    evi    clinical    disease    joint    roadmap    assays    promising    vaccines    immune    trials    facilities    significant    efficacious    infrastructure    expertise   

 Obiettivo del progetto (Objective)

'The TRANSVAC infrastructure will accelerate the pharmaceutical and clinical development of promising vaccine candidates by bringing the gap between academic research and clinical trials through carefully managing the advancement of promising vaccine candidates from preclinical animal models to early proof-of-principle studies in humans. Although expertise already exists within Europe spanning different disease types, there is currently very limited coordination between vaccine R&D groups, assay developers and vaccine producers. Unarguably, fragmentation of expertise and facilities has slowed, and in some instances distinctly impeded, the development and validation of promising vaccine candidates. To address these challenges the European vaccine development community needs to establish a collaborative vaccine development infrastructure based on shared visions and goals. The European Vaccine Initiative (EVI) and the Tuberculosis Vaccine Integrated (TBVI) Project have each demonstrated significant success in creating the know-how and infrastructures to enable the advancement of European vaccine development. In order to sustain the momentum generated by EVI and TBVI these successes will be built-upon to create an infrastructure driven by EVI, in which all stakeholders commit to sharing facilities and knowhow on vaccine development. This consortium (TRANSVAC) will comprise major European stakeholders with expertise, resources and facilities for each stage of vaccine development, from the scientific community as well as vaccine developers. Each stakeholder can add to what EVI and TBVI have already established by adding their own expertise to the TRANSVAC long term strategy. TRANSVAC will be the European driving force for vaccine development, and will be accessible to any interested parties. This consortium will initiate a new era in the innovative, harmonised and rapid development of accessible and efficacious vaccines for Europe and the rest of the world.'

Introduzione (Teaser)

The EU is fostering the implementation of a joint research infrastructure for harmonised and rapid vaccine development. This will impact the quality of research and ensure the fast development of efficacious, safe and affordable vaccines.

Descrizione progetto (Article)

Although Europe has significant research expertise on various disease types, coordination between vaccine research and development (R&D) and production is rather fragmented. Better coordination would speed up the validation of vaccine candidates and promote the most promising leads.

Funded in part by the EU, the 'European network of vaccine development and research' (TRANSVAC) project is a joint effort of leading European groups in the field of vaccine development. The ultimate goal of the consortium is to enhance coordination among stakeholders involved in all stages of vaccine development and propose a European roadmap for vaccine R&D.

Networking activities by TRANSVAC partners include the establishment of vaccine development facilities, novel vaccine formulations and testing in animal models as well as the harmonisation of immunoassays for clinical trials.

Researchers are in the process of optimising standard operating protocols (SOPs) on selected antigens and adjuvants used in vaccine formulations. A total of eight antigens used in different vaccines have so far been produced in bulk and made available. Also, a bank of cell lines suitable for good manufacturing practice (GMP) production of viral-vectored vaccines has been generated.

Additionally, the consortium is developing assays to monitor the immune responses in various animal models following vaccination. Similar assays are being developed to assess the immune responses of individuals in clinical trials, and the operating protocols are being standardised for pan-European use.

Workshop on the responsible use of animal models in pre-clinical vaccine development was attended by 30 stakeholders. Stakeholder meetings will help design a vaccine development roadmap for Europe that will promote vaccine R&D. By identifying the gaps and needs in vaccine R&D in Europe, the consortium will propose specific activities to improve these shortcomings.

The TRANSVAC infrastructure will provide services in vaccine formulation and pre-clinical testing to expedite the process of vaccine development. In the long run, these activities would benefit areas of medicine such as cancer, allergy and diabetes.

Altri progetti dello stesso programma (FP7-INFRASTRUCTURES)

TRANSVAC (2009)

European Network of Vaccine Development and Research

Read More  

6CHOICE (2008)

India-Europe cooperation to promote IPv6 adoption

Read More  

DRIHM2US (2012)

Distributed Research Infrastructure for Hydro-Meteorology to United States of America

Read More